Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Llacer Perez, C.
Romero Laorden, N.
Lozano Mejorada, R.
Piulats, J. M.
Puente, J.
Lorente Estelles, D.
Medina, A.
Cattrini, C.
Vitrone, F. M.
Almagro, E.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
